fashion -WSS

fashion

author：leisure time 2025-09-03 05:33:04 - browse：58

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Sage hopes for a blockbuster in antidepressant now before FDA

focus

leisure time

WSS

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Physician groups backed by private equity giant lobby on mergers

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Eli Lilly reports tirzepatide MASH success during Q4 earnings

What the US credit downgrade means for the economy, your finances

The high personal cost of affirmative action for Black doctors

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Amylyx, Aurinia, and IQVIA

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

The cancer drug shortage isn’t new — and neither are the solutions

Trump indictment: Who are the 'co

Novavax promises a turnaround & Lilly roils the obesity market

Having children helps parents live longer, especially after age 80

Drug repurposing or repositioning? The language matters

Adults seen as increasingly susceptible to measles

explore

Report cites 'urgent' need to recruit more diverse clinical trial participants

What the US credit downgrade means for the economy, your finances

ACIP vaccine advisory panel sees its vacancies filled

Resistance to opioid

Too many hospitalized Covid

Latigo launches with $135 million for Vertex

focus

leisure time

knowledge

knowledge